APO Research
Talk to an analyst

APO RESEARCH · REPORT

Menstrual Regulating Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Menstrual Regulating Drug Market Outlook and Growth Opportunities 2026

27 December 2025196 pages

Choose your research edition.

Industry ResearchMenstrual Regulating Drug Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Menstrual Regulating Drug Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Menstrual Regulating Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Menstrual Regulating Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Menstrual Regulating Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Menstrual Regulating Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Menstrual Regulating Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Menstrual Regulating Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Menstrual Regulating Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Menstrual Regulating Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Menstrual Regulating Drug market include Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Merck & Co., Inc., Mylan N.V., Pfizer Inc., Bayer AG, AbbVie Inc., Sun Pharmaceutical Industries Ltd. and Sandoz International GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Menstrual Regulating Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Menstrual Regulating Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Menstrual Regulating Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Menstrual Regulating Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Menstrual Regulating Drug Segment by Company

Teva Pharmaceutical Industries Ltd.

Johnson & Johnson

Merck & Co., Inc.

Mylan N.V.

Pfizer Inc.

Bayer AG

AbbVie Inc.

Sun Pharmaceutical Industries Ltd.

Sandoz International GmbH

Novartis AG

Lupin Limited

HRA Pharma

GlaxoSmithKline plc

Dr. Reddy's Laboratories Ltd.

Allergan plc

Menstrual Regulating Drug Segment by Type

Contraceptive Pills

Non-contraceptive Pills

Menstrual Regulating Drug Segment by Application

Irregular Menstruation

Menstrual Pain

Others

Menstrual Regulating Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Menstrual Regulating Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Menstrual Regulating Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Menstrual Regulating Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Menstrual Regulating Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Menstrual Regulating Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Menstrual Regulating Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Menstrual Regulating Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Menstrual Regulating Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Menstrual Regulating Drug industry.

Chapter 3: Detailed analysis of Menstrual Regulating Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Menstrual Regulating Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Menstrual Regulating Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Menstrual Regulating Drug Industry Trends Table 2. Menstrual Regulating Drug Industry Drivers Table 3. Menstrual Regulating Drug Industry Opportunities and Challenges Table 4. Menstrual Regulating Drug Industry Restraints Table 5. Global Menstrual Regulating Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Menstrual Regulating Drug Revenue Share by Company (2021-2026) Table 7. Global Menstrual Regulating Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Menstrual Regulating Drug Sales Volume Share by Company (2021-2026) Table 9. Global Menstrual Regulating Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Menstrual Regulating Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Menstrual Regulating Drug Key Company Manufacturing Base & Headquarters Table 12. Global Menstrual Regulating Drug Company, Product Type & Application Table 13. Global Menstrual Regulating Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Menstrual Regulating Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Contraceptive Pills Table 18. Significant Companies of Non-contraceptive Pills Table 19. Global Menstrual Regulating Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Menstrual Regulating Drug Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Menstrual Regulating Drug Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Menstrual Regulating Drug Sales Volume Share by Type (2021-2026) Table 23. Global Menstrual Regulating Drug Sales Volume Share by Type (2027-2032) Table 24. Global Menstrual Regulating Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Menstrual Regulating Drug Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Menstrual Regulating Drug Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Menstrual Regulating Drug Sales Value Share by Type (2021-2026) Table 28. Global Menstrual Regulating Drug Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Irregular Menstruation Table 30. Significant Companies of Menstrual Pain Table 31. Significant Companies of Others Table 32. Global Menstrual Regulating Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Menstrual Regulating Drug Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Menstrual Regulating Drug Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Menstrual Regulating Drug Sales Volume Share by Application (2021-2026) Table 36. Global Menstrual Regulating Drug Sales Volume Share by Application (2027-2032) Table 37. Global Menstrual Regulating Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Menstrual Regulating Drug Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Menstrual Regulating Drug Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Menstrual Regulating Drug Sales Value Share by Application (2021-2026) Table 41. Global Menstrual Regulating Drug Sales Value Share by Application (2027-2032) Table 42. Global Menstrual Regulating Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Menstrual Regulating Drug Sales by Region (2021-2026) & (K Units) Table 44. Global Menstrual Regulating Drug Sales Market Share by Region (2021-2026) Table 45. Global Menstrual Regulating Drug Sales by Region (2027-2032) & (K Units) Table 46. Global Menstrual Regulating Drug Sales Market Share by Region (2027-2032) Table 47. Global Menstrual Regulating Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Menstrual Regulating Drug Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Menstrual Regulating Drug Sales Value Share by Region (2021-2026) Table 50. Global Menstrual Regulating Drug Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Menstrual Regulating Drug Sales Value Share by Region (2027-2032) Table 52. Global Menstrual Regulating Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Menstrual Regulating Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Menstrual Regulating Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Menstrual Regulating Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Menstrual Regulating Drug Sales by Country (2021-2026) & (K Units) Table 57. Global Menstrual Regulating Drug Sales Market Share by Country (2021-2026) Table 58. Global Menstrual Regulating Drug Sales by Country (2027-2032) & (K Units) Table 59. Global Menstrual Regulating Drug Sales Market Share by Country (2027-2032) Table 60. Global Menstrual Regulating Drug Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Menstrual Regulating Drug Sales Value Market Share by Country (2021-2026) Table 62. Global Menstrual Regulating Drug Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Menstrual Regulating Drug Sales Value Market Share by Country (2027-2032) Table 64. Teva Pharmaceutical Industries Ltd. Company Information Table 65. Teva Pharmaceutical Industries Ltd. Business Overview Table 66. Teva Pharmaceutical Industries Ltd. Menstrual Regulating Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Teva Pharmaceutical Industries Ltd. Menstrual Regulating Drug Product Portfolio Table 68. Teva Pharmaceutical Industries Ltd. Recent Development Table 69. Johnson & Johnson Company Information Table 70. Johnson & Johnson Business Overview Table 71. Johnson & Johnson Menstrual Regulating Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Johnson & Johnson Menstrual Regulating Drug Product Portfolio Table 73. Johnson & Johnson Recent Development Table 74. Merck & Co., Inc. Company Information Table 75. Merck & Co., Inc. Business Overview Table 76. Merck & Co., Inc. Menstrual Regulating Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Merck & Co., Inc. Menstrual Regulating Drug Product Portfolio Table 78. Merck & Co., Inc. Recent Development Table 79. Mylan N.V. Company Information Table 80. Mylan N.V. Business Overview Table 81. Mylan N.V. Menstrual Regulating Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Mylan N.V. Menstrual Regulating Drug Product Portfolio Table 83. Mylan N.V. Recent Development Table 84. Pfizer Inc. Company Information Table 85. Pfizer Inc. Business Overview Table 86. Pfizer Inc. Menstrual Regulating Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Pfizer Inc. Menstrual Regulating Drug Product Portfolio Table 88. Pfizer Inc. Recent Development Table 89. Bayer AG Company Information Table 90. Bayer AG Business Overview Table 91. Bayer AG Menstrual Regulating Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Bayer AG Menstrual Regulating Drug Product Portfolio Table 93. Bayer AG Recent Development Table 94. AbbVie Inc. Company Information Table 95. AbbVie Inc. Business Overview Table 96. AbbVie Inc. Menstrual Regulating Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. AbbVie Inc. Menstrual Regulating Drug Product Portfolio Table 98. AbbVie Inc. Recent Development Table 99. Sun Pharmaceutical Industries Ltd. Company Information Table 100. Sun Pharmaceutical Industries Ltd. Business Overview Table 101. Sun Pharmaceutical Industries Ltd. Menstrual Regulating Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Sun Pharmaceutical Industries Ltd. Menstrual Regulating Drug Product Portfolio Table 103. Sun Pharmaceutical Industries Ltd. Recent Development Table 104. Sandoz International GmbH Company Information Table 105. Sandoz International GmbH Business Overview Table 106. Sandoz International GmbH Menstrual Regulating Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Sandoz International GmbH Menstrual Regulating Drug Product Portfolio Table 108. Sandoz International GmbH Recent Development Table 109. Novartis AG Company Information Table 110. Novartis AG Business Overview Table 111. Novartis AG Menstrual Regulating Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Novartis AG Menstrual Regulating Drug Product Portfolio Table 113. Novartis AG Recent Development Table 114. Lupin Limited Company Information Table 115. Lupin Limited Business Overview Table 116. Lupin Limited Menstrual Regulating Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Lupin Limited Menstrual Regulating Drug Product Portfolio Table 118. Lupin Limited Recent Development Table 119. HRA Pharma Company Information Table 120. HRA Pharma Business Overview Table 121. HRA Pharma Menstrual Regulating Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. HRA Pharma Menstrual Regulating Drug Product Portfolio Table 123. HRA Pharma Recent Development Table 124. GlaxoSmithKline plc Company Information Table 125. GlaxoSmithKline plc Business Overview Table 126. GlaxoSmithKline plc Menstrual Regulating Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. GlaxoSmithKline plc Menstrual Regulating Drug Product Portfolio Table 128. GlaxoSmithKline plc Recent Development Table 129. Dr. Reddy's Laboratories Ltd. Company Information Table 130. Dr. Reddy's Laboratories Ltd. Business Overview Table 131. Dr. Reddy's Laboratories Ltd. Menstrual Regulating Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Dr. Reddy's Laboratories Ltd. Menstrual Regulating Drug Product Portfolio Table 133. Dr. Reddy's Laboratories Ltd. Recent Development Table 134. Allergan plc Company Information Table 135. Allergan plc Business Overview Table 136. Allergan plc Menstrual Regulating Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Allergan plc Menstrual Regulating Drug Product Portfolio Table 138. Allergan plc Recent Development Table 139. Key Raw Materials Table 140. Raw Materials Key Suppliers Table 141. Menstrual Regulating Drug Distributors List Table 142. Menstrual Regulating Drug Customers List Table 143. Research Programs/Design for This Report Table 144. Authors List of This Report Table 145. Secondary Sources Table 146. Primary Sources List of Figures Figure 1. Menstrual Regulating Drug Product Image Figure 2. Global Menstrual Regulating Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Menstrual Regulating Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Menstrual Regulating Drug Sales (2021-2032) & (K Units) Figure 5. Global Menstrual Regulating Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Menstrual Regulating Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Contraceptive Pills Image Figure 10. Non-contraceptive Pills Image Figure 11. Global Menstrual Regulating Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Menstrual Regulating Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Menstrual Regulating Drug Sales Volume Share by Type (2021-2032) Figure 14. Global Menstrual Regulating Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Menstrual Regulating Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Menstrual Regulating Drug Sales Value Share by Type (2021-2032) Figure 17. Irregular Menstruation Image Figure 18. Menstrual Pain Image Figure 19. Others Image Figure 20. Global Menstrual Regulating Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Menstrual Regulating Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Menstrual Regulating Drug Sales Volume Share by Application (2021-2032) Figure 23. Global Menstrual Regulating Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Menstrual Regulating Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Menstrual Regulating Drug Sales Value Share by Application (2021-2032) Figure 26. Global Menstrual Regulating Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Menstrual Regulating Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Menstrual Regulating Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Menstrual Regulating Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Menstrual Regulating Drug Sales Value (2021-2032) & (US$ Million) Figure 31. North America Menstrual Regulating Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Menstrual Regulating Drug Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Menstrual Regulating Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Menstrual Regulating Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Menstrual Regulating Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Menstrual Regulating Drug Sales Value (2021-2032) & (US$ Million) Figure 37. South America Menstrual Regulating Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Menstrual Regulating Drug Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Menstrual Regulating Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Menstrual Regulating Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Menstrual Regulating Drug Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Menstrual Regulating Drug Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Contraceptive Pills
  • Non-contraceptive Pills
Applications
  • Irregular Menstruation
  • Menstrual Pain
  • Others
Companies covered
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan N.V.
  • Pfizer Inc.
  • Bayer AG
  • AbbVie Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Novartis AG
  • Lupin Limited
  • HRA Pharma
  • GlaxoSmithKline plc
  • Dr. Reddy's Laboratories Ltd.
  • Allergan plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Menstrual Regulating Drug Sales Value (2021-2032)
  4. 1.2.2 Global Menstrual Regulating Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Menstrual Regulating Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Menstrual Regulating Drug Market Dynamics
  1. 2.1 Menstrual Regulating Drug Industry Trends
  2. 2.2 Menstrual Regulating Drug Industry Drivers
  3. 2.3 Menstrual Regulating Drug Industry Opportunities and Challenges
  4. 2.4 Menstrual Regulating Drug Industry Restraints
3 Menstrual Regulating Drug Market by Company
  1. 3.1 Global Menstrual Regulating Drug Company Revenue Ranking in 2025
  2. 3.2 Global Menstrual Regulating Drug Revenue by Company (2021-2026)
  3. 3.3 Global Menstrual Regulating Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Menstrual Regulating Drug Average Price by Company (2021-2026)
  5. 3.5 Global Menstrual Regulating Drug Company Ranking (2024-2026)
  6. 3.6 Global Menstrual Regulating Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Menstrual Regulating Drug Company Product Type and Application
  8. 3.8 Global Menstrual Regulating Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Menstrual Regulating Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Menstrual Regulating Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Menstrual Regulating Drug Market by Type
  1. 4.1 Menstrual Regulating Drug Type Introduction
  2. 4.1.1 Contraceptive Pills
  3. 4.1.2 Non-contraceptive Pills
  4. 4.2 Global Menstrual Regulating Drug Sales Volume by Type
  5. 4.2.1 Global Menstrual Regulating Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Menstrual Regulating Drug Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Menstrual Regulating Drug Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Menstrual Regulating Drug Sales Value by Type
  9. 4.3.1 Global Menstrual Regulating Drug Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Menstrual Regulating Drug Sales Value by Type (2021-2032)
  11. 4.3.3 Global Menstrual Regulating Drug Sales Value Share by Type (2021-2032)
5 Menstrual Regulating Drug Market by Application
  1. 5.1 Menstrual Regulating Drug Application Introduction
  2. 5.1.1 Irregular Menstruation
  3. 5.1.2 Menstrual Pain
  4. 5.1.3 Others
  5. 5.2 Global Menstrual Regulating Drug Sales Volume by Application
  6. 5.2.1 Global Menstrual Regulating Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Menstrual Regulating Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Menstrual Regulating Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Menstrual Regulating Drug Sales Value by Application
  10. 5.3.1 Global Menstrual Regulating Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Menstrual Regulating Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Menstrual Regulating Drug Sales Value Share by Application (2021-2032)
6 Menstrual Regulating Drug Regional Sales and Value Analysis
  1. 6.1 Global Menstrual Regulating Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Menstrual Regulating Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Menstrual Regulating Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Menstrual Regulating Drug Sales by Region (2027-2032)
  5. 6.3 Global Menstrual Regulating Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Menstrual Regulating Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Menstrual Regulating Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Menstrual Regulating Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Menstrual Regulating Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Menstrual Regulating Drug Sales Value (2021-2032)
  12. 6.6.2 North America Menstrual Regulating Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Menstrual Regulating Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Menstrual Regulating Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Menstrual Regulating Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Menstrual Regulating Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Menstrual Regulating Drug Sales Value (2021-2032)
  21. 6.9.2 South America Menstrual Regulating Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Menstrual Regulating Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Menstrual Regulating Drug Sales Value Share by Country, 2025 VS 2032
7 Menstrual Regulating Drug Country-level Sales and Value Analysis
  1. 7.1 Global Menstrual Regulating Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Menstrual Regulating Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Menstrual Regulating Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Menstrual Regulating Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Menstrual Regulating Drug Sales by Country (2027-2032)
  6. 7.4 Global Menstrual Regulating Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Menstrual Regulating Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Menstrual Regulating Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Menstrual Regulating Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Menstrual Regulating Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Menstrual Regulating Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical Industries Ltd.
  2. 8.1.1 Teva Pharmaceutical Industries Ltd. Company Information
  3. 8.1.2 Teva Pharmaceutical Industries Ltd. Business Overview
  4. 8.1.3 Teva Pharmaceutical Industries Ltd. Menstrual Regulating Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Industries Ltd. Menstrual Regulating Drug Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Menstrual Regulating Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Menstrual Regulating Drug Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Merck & Co., Inc.
  14. 8.3.1 Merck & Co., Inc. Company Information
  15. 8.3.2 Merck & Co., Inc. Business Overview
  16. 8.3.3 Merck & Co., Inc. Menstrual Regulating Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co., Inc. Menstrual Regulating Drug Product Portfolio
  18. 8.3.5 Merck & Co., Inc. Recent Developments
  19. 8.4 Mylan N.V.
  20. 8.4.1 Mylan N.V. Company Information
  21. 8.4.2 Mylan N.V. Business Overview
  22. 8.4.3 Mylan N.V. Menstrual Regulating Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Mylan N.V. Menstrual Regulating Drug Product Portfolio
  24. 8.4.5 Mylan N.V. Recent Developments
  25. 8.5 Pfizer Inc.
  26. 8.5.1 Pfizer Inc. Company Information
  27. 8.5.2 Pfizer Inc. Business Overview
  28. 8.5.3 Pfizer Inc. Menstrual Regulating Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Inc. Menstrual Regulating Drug Product Portfolio
  30. 8.5.5 Pfizer Inc. Recent Developments
  31. 8.6 Bayer AG
  32. 8.6.1 Bayer AG Company Information
  33. 8.6.2 Bayer AG Business Overview
  34. 8.6.3 Bayer AG Menstrual Regulating Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Bayer AG Menstrual Regulating Drug Product Portfolio
  36. 8.6.5 Bayer AG Recent Developments
  37. 8.7 AbbVie Inc.
  38. 8.7.1 AbbVie Inc. Company Information
  39. 8.7.2 AbbVie Inc. Business Overview
  40. 8.7.3 AbbVie Inc. Menstrual Regulating Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 AbbVie Inc. Menstrual Regulating Drug Product Portfolio
  42. 8.7.5 AbbVie Inc. Recent Developments
  43. 8.8 Sun Pharmaceutical Industries Ltd.
  44. 8.8.1 Sun Pharmaceutical Industries Ltd. Company Information
  45. 8.8.2 Sun Pharmaceutical Industries Ltd. Business Overview
  46. 8.8.3 Sun Pharmaceutical Industries Ltd. Menstrual Regulating Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sun Pharmaceutical Industries Ltd. Menstrual Regulating Drug Product Portfolio
  48. 8.8.5 Sun Pharmaceutical Industries Ltd. Recent Developments
  49. 8.9 Sandoz International GmbH
  50. 8.9.1 Sandoz International GmbH Company Information
  51. 8.9.2 Sandoz International GmbH Business Overview
  52. 8.9.3 Sandoz International GmbH Menstrual Regulating Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Sandoz International GmbH Menstrual Regulating Drug Product Portfolio
  54. 8.9.5 Sandoz International GmbH Recent Developments
  55. 8.10 Novartis AG
  56. 8.10.1 Novartis AG Company Information
  57. 8.10.2 Novartis AG Business Overview
  58. 8.10.3 Novartis AG Menstrual Regulating Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Novartis AG Menstrual Regulating Drug Product Portfolio
  60. 8.10.5 Novartis AG Recent Developments
  61. 8.11 Lupin Limited
  62. 8.11.1 Lupin Limited Company Information
  63. 8.11.2 Lupin Limited Business Overview
  64. 8.11.3 Lupin Limited Menstrual Regulating Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Lupin Limited Menstrual Regulating Drug Product Portfolio
  66. 8.11.5 Lupin Limited Recent Developments
  67. 8.12 HRA Pharma
  68. 8.12.1 HRA Pharma Company Information
  69. 8.12.2 HRA Pharma Business Overview
  70. 8.12.3 HRA Pharma Menstrual Regulating Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 HRA Pharma Menstrual Regulating Drug Product Portfolio
  72. 8.12.5 HRA Pharma Recent Developments
  73. 8.13 GlaxoSmithKline plc
  74. 8.13.1 GlaxoSmithKline plc Company Information
  75. 8.13.2 GlaxoSmithKline plc Business Overview
  76. 8.13.3 GlaxoSmithKline plc Menstrual Regulating Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 GlaxoSmithKline plc Menstrual Regulating Drug Product Portfolio
  78. 8.13.5 GlaxoSmithKline plc Recent Developments
  79. 8.14 Dr. Reddy's Laboratories Ltd.
  80. 8.14.1 Dr. Reddy's Laboratories Ltd. Company Information
  81. 8.14.2 Dr. Reddy's Laboratories Ltd. Business Overview
  82. 8.14.3 Dr. Reddy's Laboratories Ltd. Menstrual Regulating Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Dr. Reddy's Laboratories Ltd. Menstrual Regulating Drug Product Portfolio
  84. 8.14.5 Dr. Reddy's Laboratories Ltd. Recent Developments
  85. 8.15 Allergan plc
  86. 8.15.1 Allergan plc Company Information
  87. 8.15.2 Allergan plc Business Overview
  88. 8.15.3 Allergan plc Menstrual Regulating Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Allergan plc Menstrual Regulating Drug Product Portfolio
  90. 8.15.5 Allergan plc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Menstrual Regulating Drug Value Chain Analysis
  2. 9.1.1 Menstrual Regulating Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Menstrual Regulating Drug Sales Mode & Process
  6. 9.2 Menstrual Regulating Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Menstrual Regulating Drug Distributors
  9. 9.2.3 Menstrual Regulating Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst